Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Replimune Group, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing novel oncolytic immunotherapies for cancer treatment [1]. Company Overview - Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts, with a mission to transform cancer treatment through innovative oncolytic immunotherapies [3]. - The company's proprietary RPx platform utilizes a potent HSV-1 backbone designed to maximize immunogenic cell death and induce a systemic anti-tumor immune response [3]. - The RPx platform aims to achieve local tumor destruction through selective virus-mediated killing, which releases tumor-derived antigens and modifies the tumor microenvironment to activate a robust systemic immune response [3]. - Replimune's product candidates are expected to work synergistically with both established and experimental cancer treatment modalities, allowing for versatile development either alone or in combination with other therapies [3].